Page last updated: 2024-12-06
azamethiphos
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 71482 |
| CHEMBL ID | 1867031 |
| CHEBI ID | 38578 |
| SCHEMBL ID | 26987 |
| MeSH ID | M0196937 |
Synonyms (74)
| Synonym |
|---|
| s-((6-chloro-2,3-dihydro-2-oxo-1,3-oxazolo-(4,5-b)pyridin-3-yl)methyl) o,o-dimethyl phosphorothioate |
| s-6-chloro-2,3-dihydro-2-oxo-1,3-oxazolo(4,5-b)pyridin-3-ylmethyl o,o-dimethyl phosphorothioate |
| CHEBI:38578 , |
| azamethiphos |
| s-[(6-chloro-2-oxo[1,3]oxazolo[4,5-b]pyridin-3(2h)-yl)methyl] o,o-dimethyl phosphorothioate |
| s-((6-chloro-2-oxooxazolo(4,5-b)pyridin-3(2h)-yl)methyl) o,o-dimethylphosphorothioate |
| s-[(6-chloro-2-oxo[1,3]oxazolo[4,5-b]pyridin-3(2h)-yl)methyl] o,o-dimethyl thiophosphate |
| 35575-96-3 |
| 6-chloro-3-dimethoxyphosphinoylthiomethyl-1,3-oxazolo(4,5-b)pyridin-2(3h)-one |
| brn 1086470 |
| oms no 1825 |
| azamethiphos [ban] |
| ai3-29129 |
| ciba-geigy 18809 |
| phosphorothioic acid, s-((6-chloro-2-oxooxazolo(4,5-b)pyridin-3(2h)-yl)methyl) o,o-dimethyl ester |
| cga 18809 |
| s-((6-chloro-2-oxooxazolo(4,5-b)pyridin-3(2h)-yl)methyl) o,o-dimethyl thiophosphate |
| thiophosphorsaeure-o,o-dimethyl-s-(6-chlor-oxazolo(4,5-b)pyridin-2(3h)-on-3-yl)methyl-ester |
| einecs 252-626-0 |
| c9h10cln2o5ps |
| D07479 |
| azamethiphos (ban) |
| actogard (tn) |
| NCGC00163926-01 |
| NCGC00163926-02 |
| 6-chloro-3-(dimethoxyphosphorylsulfanylmethyl)-[1,3]oxazolo[4,5-b]pyridin-2-one |
| FT-0662369 |
| NCGC00163926-03 |
| C18702 |
| tox21_301009 |
| cas-35575-96-3 |
| NCGC00254911-01 |
| dtxcid7014818 |
| dtxsid9034818 , |
| A822880 |
| s-((6-chloro-2-oxooxazolo[4,5-b]pyridin-3(2h)-yl)methyl) o,o-dimethyl phosphorothioate |
| smr000778046 |
| phosphorothioic acid, s-{(6-chloro-2-oxooxazolo(4,5-b}pyridin-3(2h)-yl}methyl} o,o-dimethyl ester |
| MLS004712087 |
| cga-18809 |
| oms-no-1825 |
| CHEMBL1867031 |
| AKOS015994780 |
| 9440r8149u , |
| unii-9440r8149u |
| FT-0602910 |
| S5085 |
| SCHEMBL26987 |
| azamethiophos |
| KS-5122 |
| azamethiphos [mi] |
| azamethiphos [mart.] |
| s-((6-chloro-2,3-dihydro-2-oxo-1,3-oxazolo-(4,5-b)pyridin-3-yl)methyl) o,o-dimethyl phosphorothioate. |
| s-((6-chloro-2-oxooxazolo(4,5-b)pyridin-3(2h)-yl)methyl) o,o-dimethyl phosphorothioate |
| rubidor |
| alfacron 10wp |
| s-[(6-chloro-2-oxo[1,3]oxazolo[4,5-b]pyridin-3(2h)-yl)methyl] o,o-dimethyl thiophosphate # |
| phosphorothioic acid, s-[(6-chloro-2-oxooxazolo[4,5-b]pyridin-3(2h)-yl)methyl] o,o-dimethyl ester |
| VNKBTWQZTQIWDV-UHFFFAOYSA-N |
| s-[(6-chloro-2-oxooxazolo[4,5-b]pyridin-3(2h)-yl)methyl] o,o-dimethylphosphorothioate |
| mfcd00867611 |
| azamethiphos, pestanal(r), analytical standard |
| azamethiphos 100 microg/ml in methanol |
| oxazolo[4,5-b]pyridine, phosphorothioic acid deriv.; azametiphos; cga 18809; ciba-geigy 18809; salmosan; snip |
| A936176 |
| s-(6-chloro-2-oxooxazolo[4,5-b]pyridin-3(2h)-yl)methyl o,o-dimethyl phosphorothioate |
| BCP17038 |
| Q793533 |
| AMY13849 |
| CCG-267754 |
| D97617 |
| phosphorothioic acid,s-[(6-chloro-2-oxooxazolo[4,5-b]pyridin-3(2h)-yl)methyl] o,o-dimethylester |
| CS-0064599 |
| HY-114899 |
Research Excerpts
Overview
Azamethiphos is an insecticide and neurotoxic agent that causes the inhibition of acetylcholinesterase (AChE) It is used to combat sea lice infestations in farmed salmonids.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Azamethiphos (AZA) is an insecticide and neurotoxic agent that causes the inhibition of acetylcholinesterase (AChE). " | ( Highly Sensitive Detection of the Insecticide Azamethiphos by Tris(2,2'-bipyridine)ruthenium(II) Electrogenerated Chemiluminescence. Barkae, TH; Xu, G; Zeid, AM, 2022) | 2.42 |
| "Azamethiphos is an organophosphate (OP) pesticide used to combat sea lice infestations in farmed salmonids." | ( Sublethal impact of short term exposure to the organophosphate pesticide azamethiphos in the marine mollusc Mytilus edulis. Canty, MN; Cooper, L; Galloway, TS; Hagger, JA; Moore, RT, 2007) | 1.29 |
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Co-treatment with azamethiphos appears to have small mitigating effects on the transcriptional response caused by deltamethrin exposure alone." | ( Transcriptional responses in Atlantic salmon (Salmo salar) exposed to deltamethrin, alone or in combination with azamethiphos. Fredriksen, BN; Lunestad, BT; Olsvik, PA; Steine, N; Ørnsrud, R, 2014) | 0.94 |
Toxicity
Azamethiphos administered dermally and orally was equally toxic to the CSMA and Yachiyo strains. Most samples taken after the releases were not toxic to test organisms in 48 h exposures.
| Excerpt | Reference | Relevance |
|---|---|---|
| " Azamethiphos administered dermally and orally was equally toxic to the CSMA and Yachiyo strains." | ( Effect of synergists on the oral and topical toxicity of azamethiphos to organophosphate-resistant houseflies (Diptera: Muscidae). Dauterman, WC; Motoyama, N; Saito, K, 1992) | 1.44 |
| " Most samples taken after the releases of azamethiphos were not toxic to test organisms in 48 h exposures and none were beyond 20 min post-release." | ( Dispersion and toxicity to non-target aquatic organisms of pesticides used to treat sea lice on salmon in net pen enclosures. Doe, K; Ernst, W; Jackman, P; Julien, G; Mackay, K; Page, F; Sutherland, T, 2001) | 0.57 |
| " The extended treatment times up to 240 min were equally safe for eels and seabass but not for trout." | ( Safety of azamethiphos in eel, seabass and trout. Cognetti-Varriale, AM; Intorre, L; Meucci, V; Monni, G; Pretti, C; Soldani, G, 2004) | 0.73 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " In this work we aimed to study the effects of deltamethrin, alone or in combination with azamethiphos, on the transcription of stress and detoxification marker genes." | ( Transcriptional responses in Atlantic salmon (Salmo salar) exposed to deltamethrin, alone or in combination with azamethiphos. Fredriksen, BN; Lunestad, BT; Olsvik, PA; Steine, N; Ørnsrud, R, 2014) | 0.83 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Preincubation with unlabelled pesticide in vitro or dosing of F344 rats with pesticide in vivo resulted in a reduction in subsequent albumin radiolabelling with (3)H-DFP, the decrease in which was used to quantify pesticide binding." | ( Albumin binding as a potential biomarker of exposure to moderately low levels of organophosphorus pesticides. Carter, WG; Lister, T; Ray, DE; Tarhoni, MH, 2008) | 0.35 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (2)
| Role | Description |
|---|---|
| EC 3.1.1.7 (acetylcholinesterase) inhibitor | An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of enzyme acetylcholinesterase (EC 3.1.1.7), which helps breaking down of acetylcholine into choline and acetic acid. |
| agrochemical | An agrochemical is a substance that is used in agriculture or horticulture. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (4)
| Class | Description |
|---|---|
| organic thiophosphate | |
| organothiophosphate insecticide | |
| organochlorine insecticide | Any organochlorine pesticide that has been used as an insecticide. |
| organochlorine acaricide | Any organochlorine pesticide that has been used as an acaricide. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (22)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| acetylcholinesterase | Homo sapiens (human) | Potency | 20.4718 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347397; AID1347398; AID1347399 |
| AR protein | Homo sapiens (human) | Potency | 40.4532 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743042; AID743054; AID743063 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 47.7534 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 52.1324 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 27.5825 | 0.0002 | 14.3764 | 60.0339 | AID588532; AID720692 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 43.1901 | 0.0008 | 17.5051 | 59.3239 | AID1159531; AID588544 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 55.0018 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 49.5252 | 0.3758 | 27.4851 | 61.6524 | AID588526; AID743217; AID743220 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 61.1306 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 45.0273 | 0.0002 | 29.3054 | 16,493.5996 | AID743080; AID743091 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 43.6412 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 22.3890 | 0.0237 | 23.2282 | 63.5986 | AID588541; AID743223 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 41.6880 | 0.0007 | 23.0674 | 1,258.9301 | AID651777; AID743085; AID743122 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 19.3312 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 43.3482 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895; AID1259385 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 19.4938 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 24.5412 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 34.6654 | 0.0578 | 21.1097 | 61.2679 | AID1159526 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 25.0616 | 0.0100 | 39.5371 | 1,122.0200 | AID588545; AID588547 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 34.3762 | 0.0376 | 17.0823 | 61.1927 | AID1259364 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 21.6506 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID743202; AID743219 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 30.6379 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (124)
Molecular Functions (34)
Ceullar Components (19)
Research
Studies (59)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (15.25) | 18.2507 |
| 2000's | 17 (28.81) | 29.6817 |
| 2010's | 21 (35.59) | 24.3611 |
| 2020's | 12 (20.34) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 27.46
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.46) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (1.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 59 (98.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||